Intuitive Surgical Inc.

ticker: ISRG step: 01 generated: 2026-05-12 source: quick-research

Intuitive Surgical, Inc. (ISRG) — Business Overview

Business Description

Intuitive Surgical is the global leader in robotic-assisted surgery (RAS), with a dominant installed base of 11,395+ da Vinci surgical systems performing 3M+ surgical procedures annually. The company is mid-rollout of da Vinci 5 (next-gen flagship platform) and rapidly scaling Ion (bronchoscopy/lung biopsy) and SP (single-port surgery). After 20+ years of effectively no soft-tissue robotic competition, Medtronic Hugo and CMR Versius now FDA-cleared in US — first serious competitive threat ever.

Revenue Model

• Instruments & Accessories (~57% of revenue, recurring): Consumables sold per-procedure ("razor-and-blade" model)
• Systems (~26%): da Vinci 5, Xi, X, SP, Ion — large capital purchases by hospitals
• Services (~17%): Annual service contracts on installed base
• ~74% recurring revenue (Instruments + Services) — exceptional for medical device company

Products & Services

Surgical Robots

• da Vinci 5: Next-gen flagship launched 2024; Force Feedback haptics; 232 placements in Q1 2026 alone (up from 147)
• da Vinci Xi/X: Predecessors still in widespread use; being replaced via trade-in upgrade program
• da Vinci SP: Single-port for tight anatomy (urology, head & neck)
• Ion: Robotic bronchoscopy for lung biopsy — 325K+ procedures cumulative; ~1,000 system installed base
• da Vinci 5 Cardiac (FDA cleared 2026): Expansion into cardiac procedures

Instruments & Accessories

• Per-procedure consumables — EndoWrist instruments, energy devices, vision system components
• Sold to hospitals at high gross margin; ~$2,000-3,000 per procedure
• Faces emerging competition from remanufactured / third-party instruments

Services

• Annual service contracts on installed base
• Software updates, AI-enabled feature releases
• Training programs

Customer Base & Go-to-Market

• Hospitals: ~11,395 da Vinci system installed base (US ~6,200; International ~5,200)
• Surgeons: Trained on da Vinci platform (~60,000+ surgeon-users globally)
• Patients: 3.15M procedures performed in 2025
• Procedures by specialty: Urology (prostatectomy), General surgery (cholecystectomy, hernia, bariatric), Gynecology (hysterectomy), Cardiothoracic (newly cleared), Head & Neck, Colorectal
• Geographic mix: ~70% US, ~30% International (US growing faster than International recently due to da Vinci 5 launch)

Competitive Position

Intuitive Surgical has the closest thing to a "moat" in medical devices: (1) 11,395+ installed base = enormous trained surgeon network with switching costs, (2) clinical evidence — 30,000+ peer-reviewed publications since 2000, (3) razor-and-blade economics with ~74% recurring revenue, (4) AI/data scale from millions of procedures recorded. New competitors (Medtronic Hugo, CMR Versius Plus, Stryker Mako for ortho, J&J Ottava) face the chicken-and-egg problem of needing surgical training programs + clinical evidence to challenge da Vinci.

Key Facts

• Founded: 1995 (Frederic Moll, Robert Younge, John Freund)
• Headquarters: Sunnyvale, CA
• Employees: ~13,000
• Exchange: NASDAQ
• Sector / Industry: Health Care / Health Care Equipment
• Market Cap: ~$220B (May 2026)
• CEO: Gary Guthart, Ph.D. (since 2010)
• Dividend: None — focuses capital on R&D + buybacks
• da Vinci installed base growth: +12% YoY (Q1 2026 vs Q1 2025)
• 2026 da Vinci procedure guidance: 13.5-15.5% growth

ticker: ISRG step: 04 generated: 2026-05-12 source: quick-research

Intuitive Surgical, Inc. (ISRG) — Financial Snapshot

Income Statement Summary

Q1 2026 Highlights

Installed Base & Placements

2026 Guidance (raised in Q1)

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate, May 2026)

• P/E (forward): ~43x | EV/Sales: ~22x | FCF Yield: ~1.2%
• Net Cash: ~$9B
• Recurring Revenue %: ~74% (Instruments + Services)

Growth Profile

ISRG is in a multi-year sustained growth phase: FY25 revenue +21%, procedures +18%. da Vinci 5 adoption accelerating (870 placements 2025 vs 362 2024 — 2.4x). Q1 2026 EBIT +40%. Force Feedback haptics rolling out. Cardiac procedures newly FDA-cleared on da Vinci 5. Tariff drag (-100bps gross margin) is the main near-term headwind.

Forward Estimates

• FY2026E Revenue: ~$11.5-11.8B (+15-17%)
• FY2026E EPS: ~$10.50 (+11%)
• FY2027E Revenue: ~$13.5B (+17%)
• FY2027E EPS: ~$12.50 (+20%)

Capital Return

• No dividend
• Buybacks: ~$0.5-1B annual modest pace
• Net cash $9B provides flexibility for M&A or accelerated buybacks
• TIKR / Citi: $700+ price targets imply ~$220B+ market cap on continued growth

ticker: ISRG step: 12 generated: 2026-05-12 source: quick-research

Intuitive Surgical, Inc. (ISRG) — Investment Catalysts & Risks

Bull Case Drivers

1. da Vinci 5 in early innings of multi-year cycle — Placements jumped from 147 (Q1 2025) → 232 (Q1 2026), with full-year placements +140% (870 in 2025 vs 362 in 2024). da Vinci 5 has ~11% higher utilization vs predecessor. Trade-in cycle for ~6,000+ Xi/X systems represents multi-year tailwind. Force Feedback haptics is a clinically meaningful innovation that competitors lack.

2. Procedure growth 13.5-15.5% durable — 2026 guidance for da Vinci procedure growth 13.5-15.5%, raised intra-year. RAS penetration remains low — global penetration in target procedures still <30%, with US >40% in mature segments (urology, gyn) but International expansion accelerating. Cardiac procedures newly FDA-cleared on da Vinci 5 opens $5-10B incremental market.

3. Strongest moat in medical devices — 11,395+ installed systems = enormous trained surgeon base with switching costs measured in years of retraining. 30,000+ peer-reviewed publications since 2000. 74% recurring revenue. Net cash $9B. Competitors face chicken-and-egg of needing clinical evidence + trained surgeon network — moat compounds.

4. 40% EBIT growth in Q1 2026 — Despite tariff drag, operating leverage strong: EBIT +40% YoY in Q1 2026. Long-term operating margin trajectory toward 40%+ as revenue scales and tariff impact fades. Combined with 13-15% revenue growth, EPS could compound at 18-25% for multiple years.

Bear Case Risks

1. 43x forward P/E — premium valuation — ISRG trades at ~43x forward EPS vs healthcare sector average ~17x. While quality and growth justify a premium, this is one of the most expensive large-cap medical devices. Any procedure growth slip below 13% or hospital capex slowdown could trigger meaningful multiple compression.

2. First serious competition in 20+ years — Medtronic Hugo and CMR Versius Plus now FDA-cleared in US for soft-tissue surgery — first credible direct competitors to da Vinci ever. While moat is strong, even small share losses on the margin could compress placements + margins. Stryker (Mako) ortho, J&J (Ottava planned), Smith+Nephew (CORI) round out competition.

3. Tariff drag + margin compression — 2026 guidance includes ~1% revenue tariff impact and 100bps gross margin compression. Combined with rising R&D for new platforms (da Vinci 5 generation, AI features, Surgical Robotics Foundation Model), near-term margin pressure may not fully reverse until 2027.

4. Pricing pressure on instruments + accessories — The high-margin "razor-and-blades" segment (~57% of revenue) faces pricing pressure as third parties push remanufactured alternatives. If hospitals successfully push through reusing/remanufacturing more instruments, the recurring revenue economics could deteriorate.

Upcoming Events

• Q2 2026 earnings (July 2026) — Procedure growth + da Vinci 5 placement trajectory; tariff offset progress
• Q3 2026 earnings (October 2026) — Cardiac procedure launch metrics
• da Vinci 5 expansion to additional specialties — Cardiac done; thoracic + others in pipeline
• Force Feedback rollout — Expanding availability throughout 2026
• Competitive launches — Medtronic Hugo + CMR Versius placement wins/losses

Analyst Sentiment

Sell-side consensus is Buy with Citi recently upgraded to Buy. Average price targets in the $620-720 range vs. recent ~$580 trading levels. TIKR sees $700+ targets justified. Bulls cite procedure growth, da Vinci 5 momentum, and "closest thing to a forever stock." Bears focus on 43x valuation and emerging competition. Consensus skews bullish — but valuation premium is the persistent debate.

Research Date

Generated: 2026-05-12